We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

224 hedge funds and large institutions have $3.48B invested in Amicus Therapeutics in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 74 increasing their positions, 80 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more call options, than puts

Call options by funds: $9.67M | Put options by funds: $3.91M

24% more capital invested

Capital invested by funds: $2.8B → $3.48B (+$680M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

8% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 80

1.68% less ownership

Funds ownership: 109.87%108.19% (-1.7%)

5% less funds holding

Funds holding: 237224 (-13)

30% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 37

Holders
224
Holders Change
-13
Holders Change %
-5.49%
% of All Funds
3.45%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
26
Increased
74
Reduced
80
Closed
37
Calls
$9.67M
Puts
$3.91M
Net Calls
+$5.76M
Net Calls Change
-$886K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
$23.2M +$2.14M +192,330 +11%
Charles Schwab
27
Charles Schwab
California
$22.6M +$966K +86,684 +5%
HRCM
28
Hood River Capital Management
Florida
$19.8M -$33.7K -3,021 -0.2%
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$19.4M -$1.5M -134,419 -7%
Two Sigma Investments
30
Two Sigma Investments
New York
$18.8M +$5.79M +519,221 +47%
Fidelity Investments
31
Fidelity Investments
Massachusetts
$18.5M +$3.3M +295,700 +23%
Citadel Advisors
32
Citadel Advisors
Florida
$18.1M -$14.5M -1,304,692 -45%
Primecap Management
33
Primecap Management
California
$17.6M -$1.09M -98,100 -6%
Goldman Sachs
34
Goldman Sachs
New York
$15.4M -$8.81M -790,905 -37%
N
35
Nuveen
North Carolina
$15M -$1.75M -157,321 -10%
SAM
36
Sectoral Asset Management
Quebec, Canada
$14.4M -$13M -1,167,722 -48%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$14.1M +$3.41M +306,228 +33%
RCAMU
38
Rothschild & Co Asset Management US
Connecticut
$14M -$524K -47,046 -4%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$13M +$85.1K +7,640 +0.7%
RSCM
40
Rock Springs Capital Management
Maryland
$11.7M
PAM
41
Panagora Asset Management
Massachusetts
$11.2M +$2.66M +238,275 +33%
GH
42
Grosvenor Holdings
Illinois
$11.1M
PCM
43
Peregrine Capital Management
Minnesota
$10.1M +$1.84M +164,919 +23%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$9.88M +$5.61M +503,500 +143%
BC
45
Brookfield Corp
Ontario, Canada
$9.24M -$502K -45,000 -5%
Nordea Investment Management
46
Nordea Investment Management
Sweden
$8.67M -$93.1K -8,358 -1%
AllianceBernstein
47
AllianceBernstein
Tennessee
$8.33M -$194K -17,423 -2%
ACM
48
Asymmetry Capital Management
California
$8.28M +$699K +62,733 +10%
Wells Fargo
49
Wells Fargo
California
$7.5M -$1.13M -101,584 -14%
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$7.29M +$505K +45,272 +8%

FOLD Hedge Fund Activity: Q4 2021 in Review

224 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2021, worth a combined $3.48B — up 24% from $2.8B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of FOLD and 26 opened new positions — a net loss of 11 holders — while 80 trimmed existing stakes and 74 added.

The largest buyer was Janus Henderson Group, adding an estimated $31.2M. The largest seller was Deutsche Bank, cutting an estimated $15M.

  • 224 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2021, down from 237 in Q3 2021.
  • Funds reported $3.48B of Amicus Therapeutics stock for Q4 2021, up 24% quarter-over-quarter.
  • 26 funds opened new Amicus Therapeutics positions in Q4 2021 and 37 closed out, a net change of -11 holders.
  • The largest Amicus Therapeutics buyer in Q4 2021 was Janus Henderson Group, an estimated $31.2M added.
  • The largest Amicus Therapeutics seller in Q4 2021 was Deutsche Bank, an estimated $15M sold.

Based on aggregated 13F filings for Q4 2021.